These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8095736)

  • 1. Low-dose depot medication in schizophrenia.
    Burnett PL; Galletly CA; Moyle RJ; Clark CR
    Schizophr Bull; 1993; 19(1):155-64. PubMed ID: 8095736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotic medication in the treatment of schizophrenia.
    Kane JM
    Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lowest effective dose of depot neuroleptics.
    Hoencamp E; Haffmans PJ; Jansen GS
    Br J Psychiatry; 1992 Mar; 160():422-3. PubMed ID: 1348655
    [No Abstract]   [Full Text] [Related]  

  • 4. Antipsychotic drug doses in a schizophrenia inpatient unit.
    Galletly CA
    Aust N Z J Psychiatry; 1992 Dec; 26(4):574-6. PubMed ID: 1362051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose response of prophylactic antipsychotics.
    Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
    J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics.
    Huttunen MO; Tuhkanen H; Haavisto E; Nyholm R; Pitkänen M; Raitasuo V; Romanov M
    Psychiatr Serv; 1996 Jan; 47(1):83-5. PubMed ID: 8925352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen.
    Weiden P; Rapkin B; Zygmunt A; Mott T; Goldman D; Frances A
    Psychiatr Serv; 1995 Oct; 46(10):1049-54. PubMed ID: 8829787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional antipsychotic medications for schizophrenia.
    Dixon LB; Lehman AF; Levine J
    Schizophr Bull; 1995; 21(4):567-77. PubMed ID: 8749885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosaging patterns in schizophrenia with depot, oral and combined neuroleptic therapy.
    Remington GJ; Prendergast P; Bezchlibnyk-Butler KZ
    Can J Psychiatry; 1993 Apr; 38(3):159-61. PubMed ID: 8098988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose medication strategies in the maintenance treatment of schizophrenia.
    Kane JM
    Schizophr Bull; 1983; 9(4):528-32. PubMed ID: 6140751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to prescribe an APAP?].
    Dassa D; Lacambre M; Vacheron MN
    Encephale; 2009 Jan; Suppl 3():S109-13. PubMed ID: 19268179
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term depot antipsychotics. A risk-benefit assessment.
    Barnes TR; Curson DA
    Drug Saf; 1994 Jun; 10(6):464-79. PubMed ID: 7917075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing the dose of depot neuroleptics in stable schizophrenia.
    Dale R; Longdon M; Seeman MV
    J Psychiatry Neurosci; 1994 Jul; 19(4):278-81. PubMed ID: 7918349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.
    Morrissette DA; Stahl SM
    CNS Spectr; 2012 Nov; 17 Suppl 1():10-21. PubMed ID: 23462201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen.
    Shriqui CL
    Can J Psychiatry; 1995 Sep; 40(7 Suppl 2):S38-48. PubMed ID: 8564916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse and rehospitalization: comparing oral and depot antipsychotics.
    Schooler NR
    J Clin Psychiatry; 2003; 64 Suppl 16():14-7. PubMed ID: 14680414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of depot neuroleptic maintenance treatment among chronic psychotic patients.
    Tuninger E; Levander S
    Acta Psychiatr Scand; 1997 Nov; 96(5):347-53. PubMed ID: 9395152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.